The invention relates to immunogenic products based on mutein amyloid &bgr; (A&bgr;) amino acid sequences, in particular to oligomers of A&bgr; muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.